Teriparatide therapy enhances devitalized femoral allograft osseointegration and biomechanics in a murine model.

Reynolds DG, Takahata M, Lerner AL, O'Keefe RJ, Schwarz EM, Awad HA

Bone13 Oct 2010Cited by 44 (Europe PMC)

PMID20950720PMCIDPMC3032022DOI10.1016/j.bone.2010.10.003PepBankPUB-20950720

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide prolonged cartilage formation at the graft-host junction at 4 weeks.
In plain wordsIn mice with femoral allografts, teriparatide prolonged cartilage formation at four weeks versus saline controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseGraft-host cartilage formation
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Source sentences
Summary
Our findings demonstrated that teriparatide induced prolonged cartilage formation at the graft-host junction at 4 weeks, which led to enhanced trabeculated bone callus formation and remarkable graft-host integration at 6-weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072001
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide enhanced trabeculated bone callus formation at 6 weeks.
In plain wordsIn mice with femoral allografts, teriparatide enhanced bone callus formation at six weeks versus saline controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabeculated bone callus formation
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Source sentences
Summary
Our findings demonstrated that teriparatide induced prolonged cartilage formation at the graft-host junction at 4 weeks, which led to enhanced trabeculated bone callus formation and remarkable graft-host integration at 6-weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072002
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide enhanced graft-host integration at 6 weeks.
In plain wordsIn mice with femoral allografts, teriparatide enhanced graft-host integration at six weeks versus saline controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseGraft-host integration
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Source sentences
Summary
Our findings demonstrated that teriparatide induced prolonged cartilage formation at the graft-host junction at 4 weeks, which led to enhanced trabeculated bone callus formation and remarkable graft-host integration at 6-weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072003
04AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide significantly increased normalized callus volume versus saline-treated controls at 6 weeks.
In plain wordsIn mice with femoral allografts, teriparatide increased normalized bone callus volume versus saline-treated controls at 6 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseNormalized callus volume
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Measurements
Normalized callus volume
1.04 mm³/mm
teriparatide
Normalized callus volume
0.54 mm³/mm
saline controls
Source sentences
Summary
Moreover, we observed a significant 2-fold increase in normalized callus volume (1.04 ± 0.3 vs. 0.54 ± 0.14 mm³/mm; p < 0.005), and Union Ratio (0.28 ± 0.07 vs. 0.13 ± 0.09; p < 0.005), compared to saline treated controls at 6-weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072004
05AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide significantly increased Union Ratio versus saline-treated controls at 6 weeks.
In plain wordsIn mice with femoral allografts, teriparatide increased the Union Ratio versus saline-treated controls at 6 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseUnion Ratio
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Measurements
Union Ratio
0.28 ratio
teriparatide
Union Ratio
0.13 ratio
saline controls
Source sentences
Summary
Moreover, we observed a significant 2-fold increase in normalized callus volume (1.04 ± 0.3 vs. 0.54 ± 0.14 mm³/mm; p < 0.005), and Union Ratio (0.28 ± 0.07 vs. 0.13 ± 0.09; p < 0.005), compared to saline treated controls at 6-weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072005
06AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide significantly increased torsional rigidity versus controls.
In plain wordsIn mice with femoral allografts, teriparatide increased resistance to twisting versus controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTorsional rigidity
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Measurements
Torsional rigidity
1175 N.mm²
teriparatide
Torsional rigidity
585 N.mm²
controls
Source sentences
Summary
Teriparatide treatment significantly increased the torsional rigidity (1175 ± 311 versus 585 ± 408 N.mm²) and yield torque (10.5 ± 4.2 versus 6.8 ± 5.5 N.mm) compared to controls.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072006
07AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, teriparatide significantly increased yield torque versus controls.
In plain wordsIn mice with femoral allografts, teriparatide increased yield torque versus controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseYield torque
Study
C57Bl/6 micen: not reported in source
Devitalized femoral allograft reconstruction
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg/kg daily · systemic injectionAs given in this study (C57Bl/6 mice).
Measurements
Yield torque
10.5 N.mm
teriparatide
Yield torque
6.8 N.mm
controls
Source sentences
Summary
Teriparatide treatment significantly increased the torsional rigidity (1175 ± 311 versus 585 ± 408 N.mm²) and yield torque (10.5 ± 4.2 versus 6.8 ± 5.5 N.mm) compared to controls.
2 context sentences(design, population, supporting numbers)
Summary · context
To address this, we investigated the effects of daily systemic injections of 40 μg/kg teriparatide (recombinant human parathyroid hormone) on the healing of devitalized allografts used to reconstruct critical femoral defects (4mm) in C57Bl/6 mice.
Summary · context
The femurs were evaluated at 4 and 6 weeks using micro CT, histology, and torsion testing.
Report a problemFND-2095072007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.